Study: docs eager for new obesity pills

With a race on to develop a new obesity treatment, Ipsos surveyed primary care doctors and found receptivity to all three clinical-stage products.

Between one-half and two-thirds of PCPs said they would likely prescribe any of the three drugs to treat their obese or overweight patients: Qnexa from Vivus, Lorqess/lorcaserin from Arena Pharmaceuticals or Contrave, from Orexigen Therapeutics.

The results were derived from an Ipsos online survey conducted as part of a Vantis Health Files (VHF) project in April 2010 among 1,500 (> 125 exposures per product) PCPs. VHF is a syndicated service designed to provide insights into the market potential for new healthcare products.

Among the three candidates, slated for FDA review within the next few months, Ipsos forecasted US retail sales to exceed $400 million annually within three to five years of launch and that Lorqess/lorcaserin has the best chance of approval.
You must be a registered member of MMM to post a comment.

Next Article in Features

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters